EP Patent

EP4396176A1 — Indole compounds and uses thereof in the treatement of cystic fibrosis

Assigned to Genzyme Corp · Expires 2024-07-10 · 2y expired

What this patent protects

The invention relates to heterocyclic compounds of formulae (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediat…

USPTO Abstract

The invention relates to heterocyclic compounds of formulae (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP4396176A1
Jurisdiction
EP
Classification
Expires
2024-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.